| Epigenomic state transitions characterize tumor progression in mouse lung adenocarcinoma LM LaFave, VK Kartha, S Ma, K Meli, I Del Priore, C Lareau, S Naranjo, ... Cancer cell 38 (2), 212-228. e13, 2020 | 174 | 2020 |
| Spatial genomics enables multi-modal study of clonal heterogeneity in tissues T Zhao, ZD Chiang, JW Morriss, LM LaFave, EM Murray, I Del Priore, ... Nature 601 (7891), 85-91, 2022 | 137 | 2022 |
| Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung CP Concepcion, S Ma, LM LaFave, A Bhutkar, M Liu, LP DeAngelo, ... Cancer discovery 12 (2), 562-585, 2022 | 60 | 2022 |
| Smarca4 inactivation promotes lineagespecific transformation and early metastatic features in the lung. Cancer Discov. 2022; 12 (2): 562–85 CP Concepcion, S Ma, LM LaFave, A Bhutkar, M Liu, LP DeAngelo, ... CD-21-0248.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 5 | |
| Historical perspective and future directions: computational science in immuno-oncology CA Ricker, K Meli, EM Van Allen Journal for Immunotherapy of Cancer 12 (1), 2024 | 2 | 2024 |
| Transposable element expression patterns in epigenetic mutational subtypes of clear cell renal cell carcinoma K Meli, CA Ricker, SY Camp, CC Smith, C Labaki, E Saad, H Soulati, ... Cancer Research 84 (6_Supplement), 5673-5673, 2024 | | 2024 |
| Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma. E Saad, C Labaki, B Miron, J Park, Z Bakouny, A Nassar, RM Saliby, ... Journal of Clinical Oncology 42 (4_suppl), 459-459, 2024 | | 2024 |
| Leveraging single-cell epigenomics to uncover regulatory programs in lung adenocarcinoma. LM LaFave, V Kartha, S Ma, K Meli, I Del Priore, C Lareau, V Sanker, ... CANCER RESEARCH 80 (11), 27-28, 2020 | | 2020 |
| Abstract PR08: Leveraging single-cell epigenomics to uncover regulatory programs in lung adenocarcinoma LM LaFave, V Kartha, S Ma, K Meli, ID Priore, C Lareau, V Sanker, ... Cancer Research 80 (11_Supplement), PR08-PR08, 2020 | | 2020 |
